Company: PSTV
Filing Date: 2025-06-09
Form Type: DRS
Source: 0000950123-25-005986
Chunk: 9

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-09
Form: DRS
Chunk 9
---
 required to pay the Additional Commitment Fee, which we may elect to pay in cash or Additional
Commitment Shares, provided that we can only issue Additional Commitment Shares if we have registered those shares for resale under the Securities Act pursuant to a separate resale registration statement.

3

Confidential Treatment Requested by Plus Therapeutics, Inc.

Pursuant to 17 C.F.R. Section 200.83

Depending on the prevailing market price of our common stock, we may not be able to sell
shares to Lincoln Park for the maximum $[ ] million over the term of the Purchase Agreement, of which Lincoln Park has already purchased $[ ] million. We are constrained by the Nasdaq limit of 19.99% of our outstanding shares that might
otherwise apply and will not sell shares in excess of 19.99% of our outstanding shares as of the date we entered into the Purchase Agreement, until we obtain stockholder approval.. We are not required or permitted to issue any shares of common stock
under the Purchase Agreement if such issuance would breach our obligations under the rules or regulations of The Nasdaq Stock Market. In addition, Lincoln Park will not be required to purchase any shares of our common stock if such sale would result
in Lincoln Park’s beneficial ownership exceeding 4.99% of the then outstanding shares of our common stock. Our inability to access a portion or the full amount available under the Purchase Agreement, in the absence of any other financing
sources, could have a material adverse effect on our business.

The extent we rely on Lincoln Park as a source of funding will depend on a
number of factors, including the prevailing market price of our common stock and the extent to which we are able to secure working capital from other sources. If obtaining sufficient funding from Lincoln Park were to prove unavailable or
prohibitively dilutive, we will need to secure another source of funding in order to satisfy our working capital needs. Even if we sell the remaining $[ ] million of shares of our common stock remaining available for sale under the Purchase
Agreement to Lincoln Park as of [ ], 2025, we may still need additional capital to finance our future production plans and working capital needs, and we may have to raise funds through the issuance of equity or debt securities. Assuming a
purchase price of $[ ] (which represents the closing price of our common stock on [ ], 2025), and that no Additional Commitment Shares are issued, the purchase by Lincoln Park of the entire 15,000,